Sponsored by
We covered an earlier iteration of this research in our SNO 2023 highlights, and the full paper is now published in the journal Nature Medicine. Researchers at ETH Zurich used a novel screening platform to test 130 repurposed neuroactive drugs on fresh glioblastoma (GBM) tumor samples. The screening identified the antidepressant vortioxetine as a promising drug candidate for GBM, and follow-up preclinical mouse testing corroborated the finding. The researchers are now preparing two clinical trials to see if vortioxetine alongside standard of care can help improve survival for GBM patients. It's worth noting that vortioxetine outperformed fluoxetine (Prozac) in the screening platform; however, human testing of vortioxetine is still needed to find appropriate dosing and to confirm safety and efficacy in GBM patients. Published real world evidence has shown that Prozac may extend survival in GBM patients, and we're eager to see if vortioxetine can do the same.